Tadej Battelino, Slovenia
University of Ljubljana Faculty of MedicinePresenter of 18 Presentations
Welcome & Introduction
Panel Discussion: How can new technologies improve diabetes management
Introduction
Live Q&A
Discussion & Closure
Summary and conclusions
Introduction
Closing Remarks
Opening Remarks
Welcome and Introductions
Closing Remarks and Farewell including Award Presentation Supported by Eli Lilly
Visualizing change: Advanced metrics in clinical care
Introduction
Discussing Diabetes Technology and Hypoglycaemia in Total Patient Care
Q&A session
SUBOPTIMAL INSULIN USE IN DIABETES MELLITUS: A SYSTEMATIC LITERATURE REVIEW
Abstract
Background and Aims
This review aimed for the first time to identify and summarize real-world evidence on the extent of suboptimal insulin use in People with Diabetes (PwD).
Methods
A systematic literature search of MEDLINE, EMBASE, and Cochrane databases identified studies reporting data on missed, incorrect, miscalculated, and mistimed insulin doses, and over/underdosing in PwD.
Results
From 3,305 publications, forty records (34 studies) were included. Seventy percent of publications were cross-sectional surveys (n=28). Publications provided data on missed (n=29) and mistimed doses (n=14), over/underdosing (n=9), and dose miscalculations (n=6). PwD reported missing basal and bolus insulin doses in all studies. Eleven records reported glycemic control was better in PwD who did not miss doses. Mistiming of insulin was reported in 14 records, with 20–45% of PwD mistiming doses. Eight records reported mistiming was associated with higher rates of hypoglycemia and/or worse glycemic control. Insulin over/underdosing varied widely across studies. Data were limited regarding dosing miscalculations, but all studies indicated that PwD experienced difficulties with insulin adjustments. Reasons for suboptimal use (n=19 records) were multifactorial, including disrupted daily routines, social situations, and hypoglycemia avoidance. Most dosing errors were unintentional.
Conclusions
Suboptimal insulin use is experienced by almost half of PwDs. This can increase the rate of hyperglycemia and hypoglycemia and is often related to social situations for hypoglycemia avoidance. Technology solutions addressing this could potentially improve diabetes management in most individuals who are actively trying to improve their metabolic control. Studies using artificial intelligence decision support systems and connected insulin pen platforms are warranted.
Introduction
Simplicity Matters: BAQSIMI - The First and Only Glucagon With Nasal Administration
Moderator of 6 Sessions
BAQSIMI and Diabetes Technology: Where Do They Fit into Total Patient Care? - Industry Symposium Supported by Eli Lilly
Session description -Welcome to BAQSIMI® (glucagon) nasal powder 3mg and Diabetes Technology: Where Do They Fit Into Total Patient Care? presented by Tadej Battelino, MD, PhD, and Marga Giménez, MD, PhD. During this symposium presentation, we will discuss how diabetes technology, hypoglycaemia, and BAQSIMI are connected within total patient care. We will share information about BAQSIMI - the first and only glucagon with nasal administration - including product attributes, clinical data, and product use and administration. In addition, we will highlight the importance of preparing people with diabetes, and those around them, for severe hypoglycaemia rescue—just in case. Thank you for joining us!
The materials for Baqsimi® (glucagon) nasal powder 3mg contained in this virtual symposium are approved following the Summary of Product Characteristics (SPC). Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).
Chronic kidney disease and diabetes: New renal and cardiovascular outcomes - Industry Symposium Supported by Sciarc GmbH
Session description - People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone. The symposium will address unmet needs in the treatment of diabetic kidney disease and presents strategies to reduce the burden. New data on kidney failure and disease progression of chronic kidney disease will be presented. Outcomes of the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes will be highlighted. In the study, finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease. Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that specifically addresses MR overactivation, a key driver of disease progression. The symposium will also focus on the clinical and practical aspects of mineralocorticoid antagonists in chronic kidney disease and type 2 diabetes.